HSBC Slashes Zydus Lifesciences Target Price Amid Legal Setback and Growth Concerns

Unknown Apr 02, 2026 500 Views

Zydus Lifesciences stock saw fresh pressure after HSBC lowered its target price to ₹855 from ₹970, reflecting growing worries over the firm's earnings prospect. This follows a US Federal Court decision that compelled Zydus to pull back its generic alternative of Myrbetriq, a key contributor t...

Stay Ahead – Explore Now! 'Made in India: A Titan Story' Captures the Power of Resilience